[1]杨海峰. 鸡肝微粒体细胞色素P450的初步研究[D].南京:南京农业大学, 2006.
YANG H F. Preliminary study on microsomal cytochrome P450 enzymes in chicken[D]. Nanjing: Nanjing agricultural university,2006.
[2]BRINK H M, GORCOM R F, PUNT P J, et al. Cytochrome P450 enzyme systems in fungi[J]. Fungal Genet Biol, 1998, 23(1):1-17.
[3]MAKIA N L, GOLDSTEIN J A. CYP2C8 is a novel target of peroxisome proliferator-activated receptor α in human liver[J]. Mol Pharmacol, 2016, 89(1): 154-164.
[4]FLEMING I. Cytochrome P450 2C is an EDHF synthase in coronary arteries[J]. Trends Cardiovasc Med, 2000, 10(4):166-170.
[5]KLOSE T S, BLAISDELL J A, GOLDSTEIN J A. Gene structure of CYP2C8, and extrahepatic distribution of the human CYP2Cs[J]. J Biochem Mol Toxicol, 1999, 13(6):289-295.
[6]DING X, KAMINSKY L S. Human extrahepatic ctyochrome P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts[J]. Annu Rev Pharmacol Toxicol, 2003, 43(1):149-173.
[7]DELOZIER T C, KISSLING G E, COULTER S J, et al. Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues[J]. Drug Metab Dispos, 2007, 35(4):682-688.
[8]NIEMI M, NEUVONEN M, DALY A K, et al. Polymorphism in CYP2C8, is associated with reduced plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2003, 74(4):380-387.
[9]TORNIO A, NIEMI M, NEUVONEN P J, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone[J]. Drug Metab Dispos, 2008, 36(1):73-80.
[10]KIRCHHEINER J, THOMAS S, BAUER S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype[J]. Clin Pharmacol Ther, 2006, 80(6):657-667.
[11]TOTAH R A, RETTIE A E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance[J]. Clin Pharmacol Ther, 2005, 77(5):341-352.
[12]FLEMING I. Cytochrome P450 2C is an EDHF synthase in coronary arteries[J]. Trends Cardiovasc Med, 2000, 10(4):166-170.
[13]张震, 富文俊, 邢宇锋,等. L-FABP/PPARα信号通路与非酒精性脂肪性肝炎关系的研究进展[J]. 山东医药, 2016, 56(8):98-100.
ZHANG Z, FU W J, XING Y F, et al. Research progress on L-FABP/PPARα signal pathway and non-alcoholic steatohepatitis[J]. Shandong Medical Journal, 2016, 56(8):98-100.
[14]DIOT C, DOUAIRE M. Characterization of a cDNA sequence encoding the peroxisome proliferator activated receptor alpha in the chicken[J]. Poult Sci, 1999, 78(8):1198-1202.
[15]熊敏. PPARs调控家禽脂肪代谢的基因网络研究[D]. 武汉:华中农业大学, 2011.
XIONG M. Gene regulatory networks of PPARS on pourtry lipid metabolism[D]. Wuhan:Huazhong Agricultural University,2011.
[16]MAKIA N L, GOLDSTEIN J A. CYP2C8 is a novel target of peroxisome proliferator-activated receptor α in human liver[J]. Mol Pharmacol, 2016, 89(1):154-164.
[17]LI H, WANG T, XU C, et al. Transcriptome profile of liver at different physiological stages reveals potential mode for lipid metabolism in laying hens[J]. BMC Genomics, 2015, 16(1):1-13.
[18]SCHNEIDER W J. Lipid transport to avian oocytes and to the developing embryo[J]. J Biomed Res, 2016, 30(3):174-180.
[19]WILLIAMS J, HARVEY S, LECLERCQ B. Plasma levels of luteinizing hormone, growth hormone, and estradiol from six weeks of age to sexual maturity in two lines of chickens selected for low or high abdominal fat content[J].Poult Sci,1986, 65(9):1782-1786.
[20]TANABE Y, NAKAMURA T, TANASE H, et al. Comparisons of plasma LH, progesterone, testosterone and estradiol concentrations in male and female chickens (Gallus domesticus) from 28 to 1141 days of age[J]. Endocrinol Jpn, 1981, 28(5):605-613.
[21]BUTLER E J. Lipid metabolism in the fowl under normal and abnormal circumstances[J]. Proc Nutr Soc, 1975, 34(1):29-34.
[22]SAARELA J, JUNG G, HERMANN M, et al. The patatin-like lipase family in Gallus gallus[J]. BMC Genomics, 2008, 9(1):1-15.
[23]SPEAKE B K, MURRAY A M, NOBLE R C. Transport and transformations of yolk lipids during development of the avian embryo[J]. Prog Lipid Res, 1998, 37(1):1-32.
[24]HERMIER D, CATHELINE D, LEGRAND P. Relationship between hepatic fatty acid desaturation and lipid secretion in the estrogenized chicken[J]. Comp Biochem Physiol A Physiol, 1996, 115(3):259-264.
[25]WILLIAMS J, HARVEY S. Plasma concentrations of luteinizing hormone growth hormone, oestradiol, testosterone and androstenedione in the domestic hen from 6 weeks of age to sexual maturity[J]. Reprod Nutr Dev, 1986, 26(2A):515-522.
[26]KLEIN-HITPASS L, SCHORPP M, WAGNER U, et al. An estrogen-responsive element derived from the 5' flanking region of the xenopus vitellogenin A2 gene functions in transfected human cells[J].Cell, 1986, 46(7):1053-1061.
[27]KLEIN-HITPASS L, RYFFEL G U, HEITLINGER E, et al. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor[J]. Nucleic Acids Res, 1988, 16(2):647-663.
[28]ZHOU H B, CARLSON K E, STOSSI F, et al. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity[J]. Bioorg Med Chem Lett, 2009, 19(1):108-110.
[29]BORD S, HORNER A, BEAVAN S, et al. Estrogen receptors alpha and beta are differentially expressed in developing human bone[J]. J Clin Endocrinol Metab, 2001, 86(5):2309-2314.
[30]李军. 海兰蛋鸡和振宁土鸡间卵黄生成的比较及雌激素对卵黄蛋白生成的调节作用[D]. 杭州:浙江大学, 2014.
LI J. A comparative study of yolk synthesis between Hyline and Zhenning layers and stimulation of 17β-estradiol on yolk proteins synthesis[D]. Hangzhou:Zhejiang University,2014.
[31]HARRINGTON W R, SHENG S, BARNETT D H, et al. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression[J]. Mol Cell Endocrinol, 2003, 206(1-2):13-22.
[32]MATTSSON A, OLSSON J A, BRUNSTROM B. Activation of estrogen receptor alpha disrupts differentiation of the reproductive organs in chicken embryos[J]. Gen Comp Endocrinol, 2011, 172(2):251-259.
[33]KOLKOVA Z, CASSLEN V, HENIC E, et al. The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer[J]. J Ovarian Res, 2012, 5(1):1257-1261.
[34]MENENDEZ D, INGA A, RESNICK M A. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences[J]. Proc Natl Acad Sci U S A, 2010, 107(4):1500-1505.
[35]TORAN-ALLERAND C D. Novel sites and mechanisms of oestrogen action in the brain[J]. Novartis Found Symp, 2000, 230(230):56-73. |